S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
NASDAQ:AGIO

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

$29.48
+0.29 (+0.99%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$29.09
▼
$29.85
50-Day Range
$26.26
▼
$31.52
52-Week Range
$16.75
▼
$34.76
Volume
449,597 shs
Average Volume
508,075 shs
Market Capitalization
$1.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.33

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
80.9% Upside
$53.33 Price Target
Short Interest
Bearish
12.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
1.29mentions of Agios Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$577,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.53) to ($6.50) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

490th out of 1,055 stocks

Pharmaceutical Preparations Industry

242nd out of 518 stocks

See Top Rated MarketRank™ Stocks Here

AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

January 30, 2023 | marketwatch.com
Cholangiocarcinoma Pipeline Market 2023 : Trends, Industry Size, Share, Emerging Trends, Top Leading Players and Forecast 2028
January 22, 2023 | americanbankingnews.com
Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells 20,000 Shares of Stock
February 1, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 15, 2023 | finance.yahoo.com
Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago
January 8, 2023 | finance.yahoo.com
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
January 7, 2023 | forbes.com
Agios Pharmaceuticals
January 3, 2023 | finance.yahoo.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
January 3, 2023 | finance.yahoo.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
February 1, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 22, 2022 | uk.finance.yahoo.com
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
December 21, 2022 | finance.yahoo.com
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
December 12, 2022 | seekingalpha.com
Agios rare blood disorder drug Pyrukynd sustains benefits in patients in long term data
December 11, 2022 | finance.yahoo.com
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
December 10, 2022 | finance.yahoo.com
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
December 6, 2022 | finance.yahoo.com
Agios Appoints Tsveta Milanova as Chief Commercial Officer
November 30, 2022 | finance.yahoo.com
Agios to Participate in December Investor Conference
November 22, 2022 | bizjournals.com
Alexion's new U.S. head is looking for 'the next generation of medicines to unpack'
November 17, 2022 | msn.com
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022 | seekingalpha.com
Agios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlook
November 17, 2022 | msn.com
Agios Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022 | finance.yahoo.com
The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup
November 11, 2022 | finance.yahoo.com
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
November 10, 2022 | finance.yahoo.com
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
November 9, 2022 | finance.yahoo.com
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 34%?
November 4, 2022 | seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript
November 3, 2022 | finance.yahoo.com
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
November 3, 2022 | finance.yahoo.com
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings
11/03/2022
Today
2/01/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
CUSIP
N/A
CIK
1439222
Web
www.agios.com
Phone
(617) 649-8600
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.33
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+80.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.60 billion
Net Margins
N/A
Pretax Margin
-3,694.98%
Return on Equity
-31.40%
Return on Assets
-28.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.65
Quick Ratio
14.55

Sales & Book Value

Annual Sales
$203.20 million
Price / Sales
7.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$23.79 per share
Price / Book
1.24

Miscellaneous

Outstanding Shares
54,940,000
Free Float
52,483,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Brian M. Goff
    Chief Executive Officer & Director
  • Cecilia Jones
    Chief Financial Officer
  • Clive Patience
    Executive Vice President-Technical Operations
  • Sarah Gheuens
    Chief Medical Officer, Head-Research & Development
  • Tsveta Milanova
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2023?

6 equities research analysts have issued twelve-month price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $96.00. On average, they predict the company's share price to reach $53.33 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of the year. Since then, AGIO stock has increased by 5.0% and is now trading at $29.48.
View the best growth stocks for 2023 here.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our AGIO earnings forecast.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($1.49) EPS for the quarter, topping analysts' consensus estimates of ($1.75) by $0.26. The biopharmaceutical company earned $3.52 million during the quarter, compared to analyst estimates of $5.24 million. During the same quarter last year, the firm earned ($1.48) earnings per share.

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.20%), Hennion & Walsh Asset Management Inc. (0.04%), Inspire Investing LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
View institutional ownership trends.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $29.48.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.62 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.65) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 390 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 2/1/2023 by MarketBeat.com Staff